June 5, 2026—Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and image analysis algorithm specifically for the TROP2 normalized membrane ratio biomarker in non-small cell lung cancer, for use as a research tool only.
The collaboration, first announced in May 2025, is built on AstraZeneca’s proprietary computational pathology algorithm, Quantitative Continuous Scoring, using Leica Biosystems’ digital pathology solutions and IHC assay development capabilities. It establishes an end-to-end solution to assess a novel biomarker that incorporates membrane and cytoplasmic expression. The collaboration will leverage Leica Biosystems’ Bond Rx research stainer, Bond-III clinical stainer, Aperio GT 450 scanner, and Aperio Halo AP image management system to support the rapid development and worldwide deployment of computational image analysis algorithms. The TROP2 NMR algorithm will be delivered through Leica Biosystems’ Aperio AI store.